Inventor · disambiguated record
Penglie Zhang
Also filed as: ZHANG PENGLIE
125 granted patents·34 pending applications·1,687 citations·filing 2000–2025
99Inventor score
Top patents by PatentIndex Score
159 records- 0198US11426364B2Immunomodulator compoundsCHEMOCENTRYX INC·Filed 2020·Granted Aug 30, 2022·10 cites·6 claims
- 0298US9834545B2Modulators of chemokine receptorsCHEMOCENTRYX INC·Filed 2016·Granted Dec 5, 2017·26 cites·33 claims
- 0398US7342013B2Benzamides and related inhibitors of factor XaMILLENNIUM PHARM INC·Filed 2006·Granted Mar 11, 2008·45 cites·16 claims
- 0498US7285565B2Benzamides and related inhibitors of factor XaMILLENNIUM PHARM INC·Filed 2005·Granted Oct 23, 2007·171 cites·8 claims
- 0598US6844367B1Benzamides and related inhibitors of factor XaMILLENNIUM PHARM INC·Filed 2000·Granted Jan 18, 2005·142 cites·10 claims
- 0698US6835739B2Benzamides and related inhibitors of factor XaMILLENNIUM PHARM INC·Filed 2003·Granted Dec 28, 2004·131 cites·11 claims
- 0798US6376515B2Benzamides and related inhibitors of factor XaCOR THERAPEUTICS INC·Filed 2001·Granted Apr 23, 2002·247 cites·72 claims
- 0897US11485708B2Compounds for treatment of PD-L1 diseasesCHEMOCENTRYX INC·Filed 2020·Granted Nov 1, 2022·9 cites·21 claims
- 0997US11266643B2Triaryl compounds for treatment of PD-L1 diseasesCHEMOCENTRYX INC·Filed 2020·Granted Mar 8, 2022·13 cites·32 claims
- 1097US11135210B2Indane-amines as PD-L1 antagonistsCHEMOCENTRYX INC·Filed 2020·Granted Oct 5, 2021·10 cites·23 claims
- 1197US10639284B2Immunomodulator compoundsCHEMOCENTRYX INC·Filed 2017·Granted May 5, 2020·17 cites·30 claims
- 1297US9809581B2Inhibitors of CXCR2CHEMOCENTRYX INC·Filed 2016·Granted Nov 7, 2017·23 cites·29 claims
- 1397US8691847B2Benzamides and related inhibitors of factor XaZHU BING-YAN·Filed 2012·Granted Apr 8, 2014·28 cites·11 claims
- 1497US7727981B2Benzamides and related inhibitors of factor XaMILLENNIUM PHARM INC·Filed 2007·Granted Jun 1, 2010·23 cites·10 claims
- 1597US7727982B2Benzamides and related inhibitors of factor XaMILLENNIUM PHARM INC·Filed 2006·Granted Jun 1, 2010·19 cites·12 claims
- 1697US7314874B2Benzamides and related inhibitors of factor XaMILLENNIUM PHARM INC·Filed 2004·Granted Jan 1, 2008·41 cites·10 claims
- 1796US11713307B2Heteroaryl-biphenyl amides for the treatment of PD-L1 diseasesCHEMOCENTRYX INC·Filed 2020·Granted Aug 1, 2023·8 cites·28 claims
- 1896US11691985B2Macrocyclic immunomodulatorsCHEMOCENTRYX INC·Filed 2021·Granted Jul 4, 2023·4 cites·20 claims
- 1996US11478460B2Diaryl substituted 6,5-fused ring compounds as C5aR inhibitorsCHEMOCENTRYX INC·Filed 2020·Granted Oct 25, 2022·3 cites·34 claims
- 2096US11059834B2Macrocyclic immunomodulatorsCHEMOCENTRYX INC·Filed 2019·Granted Jul 13, 2021·10 cites·18 claims
- 2196US11026935B2Free base crystalline form of a complement component C5a receptorCHEMOCENTRYX INC·Filed 2020·Granted Jun 8, 2021·5 cites·9 claims
- 2296US10919852B2Immunomodulator compoundsCHEMOCENTRYX INC·Filed 2018·Granted Feb 16, 2021·15 cites·25 claims
- 2396US10568874B2Indane-amines as PD-L1 antagonistsCHEMOCENTRYX INC·Filed 2019·Granted Feb 25, 2020·13 cites·26 claims
- 2496US10562896B26-5 fused rings as C5a inhibitorsCHEMOCENTRYX INC·Filed 2018·Granted Feb 18, 2020·11 cites·38 claims
- 2596US6638980B1Inhibitors of factor XaMILLENNIUM PHARM INC·Filed 2000·Granted Oct 28, 2003·91 cites·20 claims
- 2696US6534535B1Inhibitors of factor XaMILLENNIUM PHARM INC·Filed 2000·Granted Mar 18, 2003·129 cites·42 claims
- 2795US11708326B2Immunomodulator compoundsCHEMOCENTRYX INC·Filed 2020·Granted Jul 25, 2023·4 cites·25 claims
- 2895US9783540B2Substituted tetrahydropyrans as CCR2 modulatorsCHEMOCENTRYX INC·Filed 2016·Granted Oct 10, 2017·7 cites·45 claims
- 2995US8063036B2Benzamides and related inhibitors of factor XaZHU BING-YAN·Filed 2010·Granted Nov 22, 2011·11 cites·20 claims
- 3094US10683294B25-5 fused rings as C5a inhibitorsCHEMOCENTRYX INC·Filed 2018·Granted Jun 16, 2020·8 cites·31 claims
- 3194US10464934B2Substituted tetrahydropyrans as CCR2 modulatorsCHEMOCENTRYX INC·Filed 2017·Granted Nov 5, 2019·5 cites·13 claims
- 3294US10370363B2Inhibitors of CXCR2CHEMOCENTRYX INC·Filed 2017·Granted Aug 6, 2019·6 cites·13 claims
- 3394US10336736B2Modulators of chemokine receptorsCHEMOCENTRYX INC·Filed 2017·Granted Jul 2, 2019·6 cites·24 claims
- 3494US10329314B2Soluble C5aR antagonistsCHEMOCENTRYX INC·Filed 2018·Granted Jun 25, 2019·12 cites·21 claims
- 3594US9745268B2Processes and intermediates in the preparation of C5aR antagonistsCHEMOCENTRYX INC·Filed 2015·Granted Aug 29, 2017·11 cites·31 claims
- 3694US7790726B2Monocyclic and bicyclic compounds and methods of useCHEMOCENTRYX INC·Filed 2006·Granted Sep 7, 2010·34 cites·7 claims
- 3793US11479553B25-5 fused rings as C5a inhibitorsCHEMOCENTRYX INC·Filed 2020·Granted Oct 25, 2022·3 cites·24 claims
- 3893US11384079B26-5 fused rings as C5a inhibitorsCHEMOCENTRYX INC·Filed 2019·Granted Jul 12, 2022·5 cites·18 claims
- 3993US10828285B2Diaryl substituted 6,5-fused ring compounds as C5aR inhibitorsCHEMOCENTRYX INC·Filed 2018·Granted Nov 10, 2020·5 cites·27 claims
- 4093US10392405B2Macrocyclic immunomodulatorsCHEMOCENTRYX INC·Filed 2018·Granted Aug 27, 2019·13 cites·46 claims
- 4193US10266492B2Processes and intermediates in the preparation of C5aR antagonistsCHEMOCENTRYX INC·Filed 2017·Granted Apr 23, 2019·8 cites·10 claims
- 4293US7312235B2Benzamide inhibitors of factor XaMILLENNIUM PHARM INC·Filed 2002·Granted Dec 25, 2007·40 cites·20 claims
- 4392US11485737B2Diaryl substituted 5,5-fused ring compounds as C5aR inhibitorsCHEMOCENTRYX INC·Filed 2020·Granted Nov 1, 2022·2 cites·29 claims
- 4492US9169261B2CXCR7 antagonistsCHEMOCENTRYX INC·Filed 2013·Granted Oct 27, 2015·13 cites·26 claims
- 4591US11446289B2Combination therapy using C-C chemokine receptor 4 (CCR4) antagonists and one or more immune checkpoint inhibitorsCHEMOCENTRYX INC·Filed 2019·Granted Sep 20, 2022·3 cites·14 claims
- 4691US11059825B2CXCR7 antagonistsCHEMOCENTRYX INC·Filed 2019·Granted Jul 13, 2021·2 cites·11 claims
- 4791US10988464B2Modulators of chemokine receptorsCHEMOCENTRYX INC·Filed 2019·Granted Apr 27, 2021·3 cites·16 claims
- 4891US10532051B2Compositions and methods for treating inflammatory bowel disease using a combination therapy of small molecule inhibitors of C-C chemokine receptor 9 (CCR9) and anti-α4β7 integrin blocking antibodiesCHEMOCENTRYX INC·Filed 2015·Granted Jan 14, 2020·6 cites·7 claims
- 4991US8916601B2Aza-aryl 1H-pyrazol-1-YL benzene sulfonamidesCHEMOCENTRYX INC·Filed 2013·Granted Dec 23, 2014·12 cites·20 claims
- 5091US7629344B23-(imidazolyl)-pyrazolo[3,4-b]pyridinesCHEMOCENTRYX INC·Filed 2008·Granted Dec 8, 2009·13 cites·6 claims
Showing the top 50 of 159 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Penglie Zhang files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →